Arkadios Wealth Advisors Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Arkadios Wealth Advisors cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 7.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,404 shares of the company’s stock after selling 1,358 shares during the period. Arkadios Wealth Advisors’ holdings in Novo Nordisk A/S were worth $1,497,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Brooklyn Investment Group increased its position in shares of Novo Nordisk A/S by 1,634.3% during the 4th quarter. Brooklyn Investment Group now owns 2,931 shares of the company’s stock worth $252,000 after purchasing an additional 2,762 shares during the last quarter. Sax Wealth Advisors LLC purchased a new position in Novo Nordisk A/S during the fourth quarter worth about $382,000. Merit Financial Group LLC raised its stake in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Merit Financial Group LLC now owns 19,240 shares of the company’s stock valued at $1,655,000 after acquiring an additional 10,550 shares during the period. Boston Common Asset Management LLC lifted its holdings in shares of Novo Nordisk A/S by 5.9% in the 4th quarter. Boston Common Asset Management LLC now owns 53,260 shares of the company’s stock worth $4,581,000 after acquiring an additional 2,967 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC boosted its position in shares of Novo Nordisk A/S by 74.3% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 25,425 shares of the company’s stock worth $2,187,000 after purchasing an additional 10,839 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on NVO. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $78.74 on Monday. The stock has a market cap of $353.33 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a fifty day simple moving average of $97.76 and a 200-day simple moving average of $117.05. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.